이중특이성 항체 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Bispecific Antibody Market size is expected to reach USD 29.35 Billion in 2034 from USD 11.73 Billion (2025) growing at a CAGR of 10.73% during 2026-2034.

The global bispecific antibody market is witnessing rapid expansion driven by advancements in immunotherapy and oncology research. Bispecific antibodies are designed to bind two different antigens simultaneously, offering targeted and more effective treatment options, particularly in cancer therapy. Rising cancer prevalence and increasing demand for precision medicine are major contributors to market growth.

Significant investments in biotechnology research and clinical trials have accelerated the development of novel bispecific antibody candidates. Pharmaceutical companies are collaborating with research institutions to enhance therapeutic efficacy and reduce side effects. Regulatory approvals of innovative biologics have further strengthened market confidence and expanded treatment options for patients.

Future prospects remain highly positive as pipeline products continue to advance through clinical stages. Applications beyond oncology, including autoimmune and infectious diseases, are being explored. With expanding manufacturing capabilities and technological progress in antibody engineering, the bispecific antibody market is expected to achieve substantial growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Cancer Treatment
• Autoimmune Disorders
• Infectious Diseases
• Transplant Rejection

By Type

• IgG-based Bispecific Antibodies
• ScFv-based Bispecific Antibodies
• Bispecific T-cell Engager Antibodies

By Mechanism of Action

• Direct Cell-killing
• Immune Modulation
• Cytokine Release

By End-Use

• Pharmaceutical Companies
• Research Institutions
• Clinical Research Organizations

COMPANIES PROFILED

• Pfizer, Takeda Pharmaceutical, Roche, AbbVie, Eli Lilly, Bristol Myers Squibb, GSK, Genmab, Novartis, Regeneron Pharmaceuticals, Astellas Pharma, Merck, Xencor, Amgen, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BISPECIFIC ANTIBODY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Cancer Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Autoimmune Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Transplant Rejection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BISPECIFIC ANTIBODY MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. IgG-based Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. ScFv-based Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Bispecific T-cell Engager Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BISPECIFIC ANTIBODY MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Mechanism Of Action
• 6.2. Direct Cell-killing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Immune Modulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cytokine Release Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BISPECIFIC ANTIBODY MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Clinical Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BISPECIFIC ANTIBODY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Application
  • 8.2.2 By Type
  • 8.2.3 By Mechanism Of Action
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Application
  • 8.3.2 By Type
  • 8.3.3 By Mechanism Of Action
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Application
  • 8.4.2 By Type
  • 8.4.3 By Mechanism Of Action
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Application
  • 8.5.2 By Type
  • 8.5.3 By Mechanism Of Action
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Application
  • 8.6.2 By Type
  • 8.6.3 By Mechanism Of Action
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BISPECIFIC ANTIBODY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer
  • 10.2.2 Takeda Pharmaceutical
  • 10.2.3 Roche
  • 10.2.4 AbbVie
  • 10.2.5 Eli Lilly
  • 10.2.6 Bristol Myers Squibb
  • 10.2.7 GSK
  • 10.2.8 Genmab
  • 10.2.9 Novartis
  • 10.2.10 Regeneron Pharmaceuticals
  • 10.2.11 Astellas Pharma
  • 10.2.12 Merck
  • 10.2.13 Xencor
  • 10.2.14 Amgen
  • 10.2.15 Sanofi